YiLi Radiopharma Secures RMB 100 Million in Series A Financing to Accelerate Innovation and Strategic Development in Radiopharmaceuticals

VCBeat has learned at the earliest opportunity,Hangzhou Yili Pharmaceutical Co., Ltd. (hereinafter referred to as“Eli Radiopharma”)，An Innovative Radiopharmaceutical Company Dedicated to Theranostics in Targeted Radiotherapy, announced today the completion of an angel round financing amounting to hundreds of millions of RMB.

The funds raised will be used to build Eli Radiopharma’s leading innovative platform for radiopharmaceuticals, further enhancing the company’s R&D capabilities. Additionally, the funds will help accelerate the progress of the company’s clinical projects and expand its team size, thereby comprehensively driving the overall strategic development of Eli Radiopharma.

This round of financing was co-led by TAILONG VC and YuanBio Venture Capital, with participation from China Tsing Song Investment Ltd, TigerYeah Capital, Peppermint Angel Fund, and Lula Capital. The completion of this financing marks a significant step for Eli Radiopharma in realizing its vision, underscoring its strategic commitment to the integration of radiopharmaceutical diagnosis and therapy, and laying a solid foundation for the company’s sustained future growth and development.

Dr. Yu Feng, CEO of Eli Radiopharma“We are deeply honored to have earned the favor and support of our investors, which reflects their full recognition of Eli Radiopharma’s innovative capabilities and its development potential in the field of radiopharmaceuticals. Guided by the core philosophy of precision medicine, we continuously drive innovation in radiopharmaceuticals by exploring new targets, novel molecules, new radionuclides, and new indications. Leveraging our high-caliber professional team and the extensive industry experience of our partners, we are committed to developing breakthrough therapies that provide differentiated solutions for patients, accelerating the development of radiopharmaceuticals in China and globally, and contributing to the advancement of human health.”

Mr. Liu Chunguang, Managing Partner of TAILONG VCTAILONG VC stated: “TAILONG VC has been closely monitoring the development of the radiopharmaceutical industry and has strategically invested in this sector from a whole-industry-chain perspective. The integration of diagnosis and therapy using radiopharmaceuticals has become a major hotspot in the healthcare sector, and the rapid growth of this industry presents significant investment opportunities. Eli Radiopharma boasts a team with profound scientific research backgrounds and professional expertise, as well as the determination and capability to translate scientific achievements into practical applications. We are delighted to partner with Eli Radiopharma to jointly embrace future challenges and opportunities, promote the comprehensive development of radiopharmaceuticals, and contribute to the advancement of healthcare.”

Ms. Ban Bo, Partner of YuanBio Venture Capital Shenzhen Angel Fund“Radiopharmaceuticals have emerged in recent years as one of the most highly regarded innovative therapies in the biopharmaceutical sector, both domestically and internationally, with broad application prospects. Leveraging its team’s extensive expertise in radiopharmaceutical development and strong execution capabilities, Eli Radiopharma has rapidly established a comprehensive R&D platform for radiopharmaceuticals, accelerating the development of innovative products with differentiated competitive advantages. YuanBio Venture Capital is confident in Eli Radiopharma’s growth potential in the field of radiopharmaceuticals and aims to support the steady advancement of its new drug pipeline, bringing patients more effective and accessible solutions at an earlier stage.”

Eli Radiopharma, established in 2024, is a radiopharmaceutical company dedicated to the innovation and development of radiopharmaceuticals and their high-tech applications. Co-founded by a team of seasoned scientists and entrepreneurs, the company focuses on oncology and neuroscience. Upholding its core philosophy of “Innovation-Driven, Precision Medicine,” Eli Radiopharma is committed to developing cutting-edge radiopharmaceuticals to provide more precise diagnostic tools and effective therapeutic solutions for patients worldwide, jointly fostering healthier and longer lives for humanity.

TAILONG VC was established in 2021 as a professional equity investment management firm specializing in biopharmaceuticals, medical devices, and the broader health sector. The TAIKUN Fund under its management has a scale of RMB 20 billion. TAILONG VC boasts a professional and seasoned investment team, focusing on biopharmaceuticals, innovative medical devices, core CXO services and emerging sectors, as well as leading biopharmaceutical industry funds. It is committed to building a science-driven, cross-cycle value investment platform for the biopharmaceutical industry.

YuanBio Venture Capital is an investment firm focused on early-stage and growth-stage healthcare and medical companies. Headquartered in Suzhou BioBAY, it has a global reach. To date, YuanBio has invested in over 190 outstanding enterprises in the life and health sector, covering four key areas: innovative drug development, medical devices, in vitro diagnostics and precision medicine, as well as future medical technologies. The firm has achieved substantial investment returns, with 19 of its portfolio companies having listed on capital markets such as the Hong Kong Stock Exchange and the STAR Market. YuanBio Venture Capital has been repeatedly recognized as one of the Top 10 venture capital funds in China’s healthcare sector and as one of the most active healthcare investment institutions in China. By bringing together seasoned professional investors and a team of world-class scientific advisors, YuanBio possesses extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry and beyond. Leveraging its professionalism, focus, and abundant industry resources, YuanBio is committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.

Tsing Song Capital is a private equity investment firm specializing in the biotechnology and healthcare sectors, with a management team possessing deep expertise in the medical industry and extensive experience in private equity investment. Committed to growing alongside the most innovative biomedical enterprises, Tsing Song Capital drives technological and commercial innovation in China’s life sciences and healthcare industries. Adhering to a research-driven investment philosophy, the firm actively participates in the development of its portfolio companies, focusing on biotechnology, innovative drugs, novel medical devices, precision medicine and services, as well as the intersection of the broader health industry and frontier technologies. Since its establishment, the fund has invested in numerous star projects across various sub-sectors and has received multiple accolades, including being ranked among the Top 30 Best Healthcare Investment Institutions in China, the Top 50 Best Equity Investment Institutions in Future Healthcare, Best Investment Return for VC Funds, and Excellent Venture Capital Demonstration Institution.

TigerYeah Capital, established in 2014, is an independent venture capital firm under Tigermed. Focusing on equity investments in early-stage and growth-stage healthcare companies, its management team boasts extensive industry expertise, broad sector resources, and rich investment experience. To date, the firm has invested RMB 2 billion in over 100 projects, with a portfolio spanning medical devices, biopharmaceuticals, contract research organizations (CROs), and health supplements. By empowering its portfolio companies, TigerYeah Capital creates value for the development of the healthcare industry in China and globally, contributing to public health.

Established in 2015, Peppermint Angel Fund is China’s first pharmaceutical and healthcare angel investment fund dedicated to early-stage innovative R&D enterprises. It is committed to building China’s premier platform for identifying, nurturing, and incubating early-stage biotechnology projects and facilitating technology transfer. The fund’s seasoned investment team collaborates with an international “think tank” of top-tier scientists, business leaders, and entrepreneurs. It focuses on frontier life science technologies, including the development of novel drugs targeting new mechanisms and targets in oncology, autoimmunity, and anti-infectives; new therapies such as Cell and Gene Therapy (CGT) and related CRO/CDMO services; and innovative drug delivery technologies. Additionally, the fund strategically invests in precision medicine solutions, such as early disease screening and molecular imaging. By leveraging a deep understanding of the pathways and cycles of technology commercialization, the fund aims to enhance the success rate and accelerate the growth of its portfolio companies.

Lula Capital was established in 2016 and is headquartered in Hangzhou, with total assets under management exceeding RMB 1.3 billion. Lula Capital focuses on venture capital investment in the pharmaceutical and healthcare industry, prioritizing sectors such as biopharmaceuticals, cell therapy, immunotherapy, medical services, healthcare informatics, digital therapeutics, and innovative medical devices. The firm boasts an excellent investment management team and advisory board with profound insights into the healthcare industry. Adhering to the philosophy of resource sharing, the team maintains close connections with the management teams of its portfolio companies and industry experts to share industry and industrial resources.